A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor‐Positive Breast Cancer, Non‐small Cell Lung Cancer, or Melanoma. This evidence concerns the gene NR4A1 and melanoma.